Transcription of CALQUENCE PRESCRIBING INFORMATION
{{id}} {{{paragraph}}}
Example: marketing
CALQUENCE PRESCRIBING INFORMATION
US-33441 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the INFORMATION needed to use CALQUENCE safely and effectively. See full PRESCRIBING INFORMATION for (acalabrutinib) capsules, for oral use Initial Approval: 2017-------------------------------- RECENT MAJOR CHANGES ---------------------------------Indicat ions and Usage ( ) 11/2019 Dosage and Administration ( ) 11/2019--------------------------------- INDICATIONS AND USAGE ---------------------------------CALQUEN CE is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Monitor patients for skin cancers and advise protection from sun exposure. 5.5 Atrial Fibrillation and Flutter Grade 3 atrial fibrillation or flutter occurred in 1.1% of 1029 patients treated with CALQUENCE, with all grades of atrial fibrillation or flutter reported in 4.1% of all patients.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: